Full text is available at the source.
Abstract
A duodenal ulcer perforation was observed in a patient two weeks after increasing tirzepatide dosage from 2.5 mg to 5 mg weekly.
- The patient experienced colicky abdominal pain following the dose escalation of tirzepatide.
- Imaging revealed a localized retroperitoneal perforation of the duodenum.
- Management included intravenous antibiotics, proton pump inhibitors, and bowel rest.
- The patient showed clinical improvement and was discharged after treatment.
- The case raises questions about a potential association between tirzepatide and upper gastrointestinal issues.
Simplified